Ratings by Morgan Stanley (Andrew Galler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/19/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/13/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/8/2023 | Amicus Therapeutics | FOLD | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/3/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2023 | Amicus Therapeutics | FOLD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/10/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/5/2023 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/9/2022 | Silence Therapeutics | SLN | New Coverage | Equalweight (N/A) |
15.55 (22.64) |
45.59% | Details | |
| 10/28/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/13/2022 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/13/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2022 | Halozyme Therapeutics | HALO | New Coverage | Overweight (N/A) |
39.41 (38.64) |
-1.95% | Details | |
| 9/9/2022 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
49.98 (55.68) |
11.4% | Details | |
| 9/9/2022 | Amicus Therapeutics | FOLD | New Coverage | Equalweight (N/A) |
11.49 (10.61) |
-7.66% | Details | |
| 9/9/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
43.45 (40.68) |
-6.38% | Details | |
| 9/9/2022 | Vir Biotechnology | VIR | New Coverage | Underweight (N/A) |
22.02 (7.95) |
-63.9% | Details | |
| 9/9/2022 | Arrowhead Pharma | ARWR | New Coverage | Equalweight (N/A) |
39.17 (22.33) |
-42.99% | Details | |
| 9/9/2022 | PTC Therapeutics | PTCT | New Coverage | Equalweight (N/A) |
53.79 (25.32) |
-52.93% | Details | |
| 9/9/2022 | Alnylam Pharmaceuticals | ALNY | New Coverage | Equalweight (N/A) |
208.86 (144.41) |
-30.86% | Details |
